Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the infrastructure, wind power, marine/life sciences, pipelines, mobile/off-highway equipment, oil, gas, and mining markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and direct and independent distributors under the DJO brand. Colfax Corporation was founded in 1860 and is headquartered in Annapolis Junction, Maryland.
IPO Year: 2008
Exchange: NYSE
Website: colfaxcorp.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2022 | $8.00 → $7.00 | Sector Perform | RBC Capital |
| 2/23/2022 | $58.00 → $52.00 | Buy | Stifel |
| 2/8/2022 | Buy → Neutral | Seaport Global | |
| 1/28/2022 | $51.00 → $45.00 | Equal-Weight | Morgan Stanley |
| 1/14/2022 | $56.00 → $51.00 | Equal-Weight | Morgan Stanley |
| 1/6/2022 | $45.00 | Hold | Loop Capital |
| 11/5/2021 | $57.00 → $60.00 | Overweight | Keybanc |
| 10/20/2021 | $12.00 → $9.00 | Outperform → Sector Perform | RBC Capital |
| 10/7/2021 | $51.00 → $50.00 | Equal-Weight | Morgan Stanley |
| 10/4/2021 | $44.00 → $43.00 | Underweight | Barclays |
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
RBC Capital reiterated coverage of Canfor Pulp Products with a rating of Sector Perform and set a new price target of $7.00 from $8.00 previously
Stifel reiterated coverage of Colfax with a rating of Buy and set a new price target of $52.00 from $58.00 previously
Seaport Global downgraded Colfax from Buy to Neutral
Morgan Stanley reiterated coverage of Colfax with a rating of Equal-Weight and set a new price target of $45.00 from $51.00 previously
Morgan Stanley reiterated coverage of Colfax with a rating of Equal-Weight and set a new price target of $51.00 from $56.00 previously
Loop Capital initiated coverage of Colfax with a rating of Hold and set a new price target of $45.00
Keybanc reiterated coverage of Colfax with a rating of Overweight and set a new price target of $60.00 from $57.00 previously
RBC Capital downgraded Canfor Pulp Products from Outperform to Sector Perform and set a new price target of $9.00 from $12.00 previously
Morgan Stanley reiterated coverage of Colfax with a rating of Equal-Weight and set a new price target of $50.00 from $51.00 previously
Barclays reiterated coverage of Colfax with a rating of Underweight and set a new price target of $43.00 from $44.00 previously
8-K - Enovis CORP (0001420800) (Filer)
11-K - Enovis CORP (0001420800) (Filer)
8-K - Enovis CORP (0001420800) (Filer)
SD - Enovis CORP (0001420800) (Filer)
8-K - Enovis CORP (0001420800) (Filer)
10-Q - Enovis CORP (0001420800) (Filer)
DEFA14A - Enovis CORP (0001420800) (Filer)
DEF 14A - Enovis CORP (0001420800) (Filer)
8-K - Enovis CORP (0001420800) (Filer)
8-K - Colfax CORP (0001420800) (Filer)
Wilmington, DE, April 05, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation ("Enovis" or the "Company") (NYSE:ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, announced today the completion of its previously announced separation (the "Separation") of its fabrication technology business into an independent, publicly traded company, ESAB Corporation ("ESAB") (NYSE:ESAB). Immediately following the Separation, Enovis effected its previously announced reverse stock split of all issued and outstanding shares of Enovis common stock at a one-for-three ratio. Enovis and ESAB common stock will each begin regular-way trading today, April 5, 2022, on t
NEW YORK, March 30, 2022 /PRNewswire/ -- ESAB Corp. (NYSE:ESAB) will be added to the S&P MidCap 400 effective prior to the opening of trading on Tuesday, April 5. Effective prior to the opening of trading on Wednesday, April 6, S&P MidCap 400 constituent PROG Holdings Inc. (NYSE:PRG) will replace Fiesta Restaurant Group Inc. (NASD: FRGI) in the S&P SmallCap 600. S&P MidCap 400 constituent Colfax Corp. (NYSE:CFX) is spinning off ESAB in a transaction expected to be completed on April 5. Post spin-off, Colfax will be renamed Enovis Corp. (NYSE:ENOV) and will remain in the S&P MidCap 400. PROG Holdings is more representative of the small-cap market space and Fiesta Restaurant Group is no longer
Wilmington, DE, March 28, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company which will renamed Enovis Corporation ("Enovis") following the expected April 4, 2022 consummation of the Company's previously announced spin-off of its fabrication technology business (the "Separation"), which will operate as ESAB Corporation ("ESAB") after the Separation, today announced the future composition of the full ESAB Board of Directors (the "Board"). Following the Separation, Mitchell P. Rales will serve as chairman of the Board, and current Colfax directors Patrick W. Allender, Rhonda L. Jordan, Didier Teirlinck and Rajiv Vinnakota will serve as directo
"When-issued" trading of ESAB and Colfax ex-distribution common stock expected to begin on March 21, 2022Record date for distribution of ESAB common stock will be March 22, 2022Distribution Date expected to be April 4, 2022 Wilmington DE,, March 14, 2022 (GLOBE NEWSWIRE) -- —Colfax Corporation ("Colfax") (NYSE:CFX) today announced that its Board of Directors has declared (a) a pro rata distribution of 90% of the outstanding common stock of ESAB Corporation ("ESAB") to Colfax shareholders of record as of the close of business on March 22, 2022 (the "Record Date"), and (b) that the previously announced reverse stock split of all issued and outstanding shares of Colfax Common Stock will be e
Wilmington DE,, March 11, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced the future composition of the Board of Directors (the "Board") of the Company, which will be renamed Enovis Corporation ("Enovis") upon the consummation of the Company's previously announced spin-off (the "Separation") of its existing fabrication technology business, which will operate as ESAB Corporation. Following the Separation, Mitchell P. Rales will continue to serve as chairman of the Board, and current Colfax directors Liam Kelly, Philip Okala, Clayton Perfall, Rajiv Vinnakota, Sharon Wienbar, and Matt Trerotola will remain in their current r
Wilmington, DE, March 07, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation ("Colfax" or the "Company") (NYSE:CFX), a leading diversified technology company, announced today that it had given notice of its intention to redeem €350 million principal amount representing of its outstanding 3.250% Senior Notes due 2025 (ISIN Numbers XS1599407217, XS1599406839) (the "2025 Notes") and $300 million principal amount representing all of its outstanding 6.375% Senior Notes due 2026 (CUSIP Numbers 15723RAC8, U1581TAB4) (the "2026 Notes" and, together with the 2025 Notes, the "Notes") on April 7, 2022 (the "Redemption Date"), and is conditioned upon the receipt of aggregate gross proceeds from the completio
Through Recent Acquisitions and Internal Development, DJO makes its mark in the industry as a Foot & Ankle Business DJO®, a subsidiary of Colfax Corporation (NYSE:CFX) and a leading global provider of medical technologies to get and keep people moving, today announced it will showcase their growing Foot & Ankle offerings at the 2022 American College of Foot and Ankle Surgeons (ACFAS) Scientific Conference in Austin from February 21-24, 2022. DJO has created a dedicated foot and ankle business unit that expands the company's mission of Powering Motion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220222005128/en/The DJO DynaNai
Strong operating performance supported $0.06 EPS from continuing operations and $0.59 of adjusted EPSAchieved a strong quarter of cash flow, contributing to full year operating cash flow of $356 million and free cash flow of $277 millionPositioned for separation into two independent public companies near the end of the first quarter 2022 with strong growth outlooks for both businesses Wilmington, DE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced its financial results for the fourth quarter and fiscal year 2021 and provided additional updates. The Company reported fourth quarter net income from c
Wilmington DE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the fourth quarter and fiscal year 2021 on the morning of Tuesday, February 22, 2022. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 7466839 and through webcast via Colfax's website www.colfaxcorp.com under the "Investors" section. Colfax's financial results
Wilmington, DE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, announced today that it will be presenting at the J.P. Morgan Healthcare Conference on January 12, at 3:00 pm (EST). A live presentation of this event will be available via Colfax's website at www.colfaxcorp.com under the "Investors" section. Replays will also be available on the Company's website following the event. About Colfax Corporation Colfax Corporation (NYSE:CFX) is a leading diversified technology company that provides orthopedic and fabrication technology products and services to customers around the world, principally under the DJO a
Strong operating performance supported $0.06 EPS from continuing operations and $0.59 of adjusted EPSAchieved a strong quarter of cash flow, contributing to full year operating cash flow of $356 million and free cash flow of $277 millionPositioned for separation into two independent public companies near the end of the first quarter 2022 with strong growth outlooks for both businesses Wilmington, DE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced its financial results for the fourth quarter and fiscal year 2021 and provided additional updates. The Company reported fourth quarter net income from c
Wilmington DE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the fourth quarter and fiscal year 2021 on the morning of Tuesday, February 22, 2022. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 7466839 and through webcast via Colfax's website www.colfaxcorp.com under the "Investors" section. Colfax's financial results
Posted $0.17 EPS from continuing operations and $0.54 of adjusted EPSIncreased sales 20% to $966 million including a 15% organic sales-per-day improvementReported strong progress on integration of acquisitionsAnnounced continued progress to Q1 2022 separation including new post-separation name for MedTech growth company WILMINGTON, DE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced its financial results for the third quarter of 2021 and provided other updates. The Company reported third quarter net income from continuing operations of $27 million, or $0
WILMINGTON, DE, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the third quarter of 2021 on the morning of Thursday, November 4, 2021. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-888-771-4371 (U.S. callers) and +1-847-585-4405 (International callers) and referencing the conference ID number 50243903 and through webcast via Colfax's website www.colfaxcorp.com under the "Investors" section. Colfax's financial results press release and supp
Reported $0.19 EPS from continuing operations and achieved $0.56 of adjusted EPS, raised FY 2021 adjusted EPS guidance range to $2.10-$2.20Signed agreement to acquire Mathys Bettlach AG to expand fast-growing MedTech Reconstructive business outside of North AmericaMade significant progress on separation into two independent public companies, continuing to target Q1 2022 completion WILMINGTON, DE, July 28, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE:CFX), a leading diversified technology company, today announced its financial results for the second quarter of 2021. The Company reported second quarter net income from continuing operations attributable to Colfax of
Acquisition expands foot and ankle business and adds innovative shape memory technologies DJO, a subsidiary of Colfax Corporation (NYSE:CFX) and a leading global provider of medical technologies to get and keep people moving, today announced that it has completed the acquisition of MedShape, Inc., a privately held orthopedic medical device company founded in 2005. MedShape® provides innovative surgical solutions for foot and ankle surgeons using its patented superelastic nickel titanium (NiTiNOL) shape memory alloy and shape memory polymer technologies. The acquired business' portfolio includes innovative devices for fracture fixation, joint fusion and soft tissue injury repair that utili
• Reported $0.29 EPS from continuing operations and achieved $0.51 of adjusted EPS• Recently acquired two high-growth, high-gross margin medical technology businesses • Announced 2021 outlook with expectations for significant revenue, profit and cash flow growth • Scheduled Investor Day for Thursday, March 11, 2021 ANNAPOLIS JUNCTION, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its financial results for the fourth quarter of 2020. The Company earned fourth quarter net income from continuing operations of $41 million, or $0.29 per share, and adjusted earnings of $0
DALLAS--(BUSINESS WIRE)--DJO, LLC (DJO or the Company), a leading global provider of medical technologies to get and keep people moving, today announced the acquisition of Trilliant Surgical®, a national provider of foot and ankle orthopedic implants. The acquisition of Trilliant Surgical’s leading product technologies and clinical efficacy supports DJO’s focused expansion into the adjacent high-growth $1 billion US foot and ankle market. In addition to having a broad product portfolio that covers the full universe of foot recon/fixation procedures, Trilliant Surgical is the only provider of the novel Arsenal Foot Plating System™. With unique features designed for greater flexibi
DALLAS--(BUSINESS WIRE)--DJO, LLC (“DJO” or the “Company”), a leading global provider of medical technologies to get and keep people moving, today announced the acquisition of LiteCure®, the market leader in therapeutic laser technology for human and animal health. This purchase further extends DJO’s strength as the global market leader in recovery sciences and allows the company to deliver unparalleled innovation to its customers and their patients. “The LiteCure portfolio was a natural fit for the DJO Recovery Sciences business, bringing together a joint passion for innovation and clinically proven technology,” said Brady Shirley, DJO CEO. “The acquisition will strengthen our
SC 13G - Enovis CORP (0001420800) (Subject)
SC 13G/A - Colfax CORP (0001420800) (Subject)
SC 13G/A - Colfax CORP (0001420800) (Subject)
SC 13G - Colfax CORP (0001420800) (Subject)
SC 13G/A - Colfax CORP (0001420800) (Subject)
SC 13G/A - Colfax CORP (0001420800) (Subject)
SC 13G/A - Colfax CORP (0001420800) (Subject)
SC 13G/A - Colfax CORP (0001420800) (Subject)
SC 13G/A - Colfax CORP (0001420800) (Subject)
SC 13G/A - Colfax CORP (0001420800) (Subject)